substance p has been researched along with 2019 Novel Coronavirus Disease in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 9 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mehboob, R | 1 |
| Di Primo, C; Dilly, S; Goupil-Lamy, A; Henri, J; Minder, L; Mohanasundaram, K; Slama Schwok, A | 1 |
| Albanese, M; Boffa, L; Bovenzi, R; Di Girolamo, S; Greco, A; Grillo, P; Lattanzi, R; Loccisano, L; Maftei, D; Maurizi, R; Mercuri, NB; Passali, FM; Schirinzi, T; Severini, C; Simonetta, C; Vincenzi, M; Zenuni, H | 1 |
| Baird, AE; Conte, HA; Diamandis, EP; Fraser, DD; Janket, SJ; Prassas, I; Sohaei, D; Tamimi, F | 1 |
| Aguirre-Siancas, EE; Alzamora-Gonzales, L; Becerra-Bravo, M; Colona-Vallejos, E; Ruiz-Ramirez, E | 1 |
| Theoharides, TC | 1 |
| Lavezzi, AM; Mehboob, R | 1 |
| Andersen, ML; Facina, AS; Tomimori, J; Tufik, S; Xerfan, EMS | 1 |
| Karamyan, VT | 1 |
3 review(s) available for substance p and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Neurokinin-1 Receptor as a potential drug target for COVID-19 treatment.
Topics: COVID-19; COVID-19 Drug Treatment; Drug Development; Humans; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; SARS-CoV-2; Substance P | 2021 |
Tachykinins and the potential causal factors for post-COVID-19 condition.
Topics: COVID-19; Humans; Neuropeptides; Receptors, Tachykinin; Substance P; Tachykinins | 2023 |
Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?
Topics: Animals; Bradykinin; COVID-19; Cytokines; Humans; Microvessels; Neprilysin; Neurotensin; Post-Acute COVID-19 Syndrome; Substance P | 2021 |
6 other study(ies) available for substance p and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Neuropeptides, New Ligands of SARS-CoV-2 Nucleoprotein, a Potential Link between Replication, Inflammation and Neurotransmission.
Topics: COVID-19; Humans; Inflammation; Ligands; Neuropeptides; Nucleoproteins; Post-Acute COVID-19 Syndrome; SARS-CoV-2; Substance P; Synaptic Transmission | 2022 |
Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction.
Topics: COVID-19; Humans; Neurons; Olfaction Disorders; Post-Acute COVID-19 Syndrome; SARS-CoV-2; Smell; Substance P | 2023 |
[Substance P, proinflammatory cytokines, transient receptor potential vanilloid subtype 1 and COVID-19: A working hypothesis].
Topics: COVID-19; Cytokine Release Syndrome; Cytokines; Humans; Models, Immunological; Neuroimmunomodulation; Neuropeptides; SARS-CoV-2; Substance P; TRPV Cation Channels | 2021 |
Potential association of mast cells with coronavirus disease 2019.
Topics: Cell Communication; Cholecalciferol; COVID-19; COVID-19 Drug Treatment; Cromolyn Sodium; Cyproheptadine; Cytokines; Famotidine; Histamine; Histamine Antagonists; Humans; Lung; Luteolin; Macrophages; Mast Cells; SARS-CoV-2; Severity of Illness Index; Substance P | 2021 |
Neuropathological explanation of minimal COVID-19 infection rate in newborns, infants and children - a mystery so far. New insight into the role of Substance P.
Topics: Child; Child, Preschool; COVID-19; Female; Humans; Infant; Infant, Newborn; Male; Substance P | 2021 |
The role of sleep in telogen effluvium and trichodynia: A commentary in the context of the current pandemic.
Topics: Animals; Anxiety; COVID-19; Hair Diseases; Humans; Mice; SARS-CoV-2; Sleep; Sleep Wake Disorders; Stress, Psychological; Substance P | 2021 |